Actively Recruiting

Phase Not Applicable
Age: 6Months - 36Months
All Genders
ID07153549

A Parallel-Group, Randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Biolizin, a Zinc-Containing Supplement, in Improving Functional Poor Appetite in Children Aged 6 to 36 Months

Led by Haiphong University of Medicine and Pharmacy · Updated on 2026-01-30

110

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Poor appetite is common in young children and can affect their nutrient intake and eating behavior. This research aims to evaluate whether a zinc-containing oral supplement called Biolizin syrup can improve eating behavior in children aged 6 to 36 months who have poor appetite without a clear medical cause. The study is randomized and controlled, focusing on changes in feeding difficulty and eating behavior over 42 days. Children in the study receive either Biolizin syrup, taken once or twice daily according to age-based dosing for 42 days along with caregiver counseling on responsive feeding, or they receive only the caregiver counseling without the supplement. Caregivers attend clinic visits at Day 0, Day 7, Day 21, and Day 42 to receive counseling, report feeding behavior, and monitor adherence. Use of other zinc products or appetite stimulants is not allowed. Participants undergo measurements of weight and height at each visit, and caregivers complete validated questionnaires on feeding difficulties and eating behavior. Safety is monitored through adverse event review and laboratory tests at baseline and Day 42, including possible serum zinc levels. The main outcome measured is the change in feeding difficulty score from the start to Day 42. Secondary outcomes include changes in eating behavior subscales, growth indices, serum zinc, and overall safety throughout the study.

CONDITIONS

Brief Title

Biolizin for Improving Functional Poor Appetite in Children Aged 6 to 36 Months (CTBE2502)

Who Can Participate

Age: 6Months - 36Months
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Children aged 6 to 36 months at screening
  • Functional poor appetite lasting 2 weeks or more
  • Poor appetite shows as reduced food intake, prolonged meal duration over 30 minutes, refusal of familiar foods, or oppositional feeding behaviors
  • No obvious medical cause for poor appetite such as acute infection or metabolic disease
  • Weight not below -2 standard deviations compared with WHO growth standards
  • Parent or guardian provides written informed consent
Not Eligible

You will not qualify if you...

  • Acute or chronic illnesses affecting intake or absorption, including infections (tonsillitis, pneumonia, otitis media, viral illness, diarrhea) or chronic diseases (celiac disease, liver or kidney disease, diabetes)
  • Neurodevelopmental or neurological disorders impairing feeding (cerebral palsy, autism spectrum disorder, developmental delay)
  • Current or recent use of medications affecting appetite or digestion such as corticosteroids, antiepileptics, or antibiotics
  • Use of zinc-containing products or appetite stimulants within 7 days before screening
  • Known allergy to any component of the study product
  • Malabsorption, severe malnutrition, or need for specialized nutrition plans
  • Caregiver nonadherence or high risk of loss to follow-up as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 42 days

Participants take the Biolizin oral zinc-containing supplement once or twice daily for 42 consecutive days along with standardized caregiver counseling on responsive feeding at each clinic visit. Caregivers complete dosing diaries and adherence is monitored using returned bottle counts. Safety labs and assessments are conducted.

4 visits (in-person) at Day 0, Day 7, Day 21, and Day 42

Trial Site Locations

Total: 1 location

1

Clinical Trial and Bioequivalence Center

Haiphong, Hai Phong, Vietnam, 180000

Actively Recruiting

Loading map...

Research Team

P

Phuong Thi Thu Nguyen, MD, PhD

A

Anh Van Tran, MSc

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here